Reaction
Plasma Cell Myeloma Refractory reporting signals
As of the last recalculation, Plasma Cell Myeloma Refractory appears in 1,279 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is CARFILZOMIB (PRR 411.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Carfilzomib | 459 | 411.4 | 418.2 |
| Daratumumab | 498 | 331.6 | 335.8 |
| Bortezomib | 744 | 322.3 | 325.0 |
| Selinexor | 62 | 122.4 | 123.3 |
| Ixazomib | 138 | 87.4 | 87.8 |
| Melphalan | 104 | 80.9 | 81.3 |
| Pomalidomide | 358 | 78.3 | 78.6 |
| Melphalan Hydrochloride | 105 | 74.2 | 74.5 |
| Dexamethasone 1.5 Mg | 643 | 70.8 | 71.0 |
| Dexamethasone | 643 | 69.9 | 70.1 |
| Thalidomide | 119 | 58.1 | 58.2 |
| Lenalidomide | 625 | 46.1 | 46.2 |
| Cyclophosphamide Injection, Solution | 285 | 33.4 | 33.5 |
| Cyclophosphamide | 285 | 33.4 | 33.5 |
| Cyclophosphamide For Injection | 285 | 33.4 | 33.5 |
| Dexamethasone Sodium Phosphate | 18 | 29.2 | 29.3 |
| Etoposide | 99 | 23.7 | 23.7 |
| Doxorubicin | 115 | 23.0 | 23.0 |
| Thiotepa | 13 | 22.4 | 22.4 |
| Doxorubicin Hydrochloride | 43 | 22.1 | 22.2 |
| Bendamustine Hcl | 20 | 21.3 | 21.3 |
| Bendamustine Hydrochloride | 14 | 19.2 | 19.2 |
| Posaconazole Delayed-Release | 10 | 14.9 | 14.9 |
| Cisplatin | 67 | 14.7 | 14.7 |
| Fludarabine Phosphate | 31 | 13.1 | 13.1 |
| Dutasteride | 6 | 12.1 | 12.1 |
| Mesna Injection | 6 | 11.9 | 11.9 |
| Mesna | 6 | 11.6 | 11.7 |
| Acyclovir | 74 | 11.1 | 11.1 |
| Prochlorperazine Maleate | 6 | 10.6 | 10.6 |
| Posaconazole | 10 | 10.1 | 10.1 |
| Venetoclax | 32 | 8.6 | 8.7 |